Cabergoline in prolactinomas

Anna B. Fierz; David I. Kaufman; Andrew G. Lee; Eric R. Eggenberger; Keith E. Friend

doi:10.1076/noph.22.1.37.3741

Cabergoline in prolactinomas

Anna B. Fierz, David I. Kaufman, Andrew G. Lee, Eric R. Eggenberger, Keith E. Friend

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Cabergoline is a potent, D2-selective new dopamine agonist with a half- life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.

Original language	English (US)
Pages (from-to)	37-46
Number of pages	10
Journal	Neuro-Ophthalmology
Volume	22
Issue number	1
DOIs	https://doi.org/10.1076/noph.22.1.37.3741
State	Published - 1999

Keywords

Bromocriptine resistance
Cabergoline
Metastatic prolactinomas
Prolactinomas

ASJC Scopus subject areas

Clinical Neurology
Ophthalmology

Access to Document

10.1076/noph.22.1.37.3741

Cite this

@article{c5b40e51591543e8abb99df42cf48e48,

title = "Cabergoline in prolactinomas",

abstract = "Cabergoline is a potent, D2-selective new dopamine agonist with a half- life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.",

keywords = "Bromocriptine resistance, Cabergoline, Metastatic prolactinomas, Prolactinomas",

author = "Fierz, {Anna B.} and Kaufman, {David I.} and Lee, {Andrew G.} and Eggenberger, {Eric R.} and Friend, {Keith E.}",

note = "Funding Information: Dr. D.I. Kaufman Professor and Director Center for Clinical Neurosciences and Ophthalmology A-217 Clinical Center 138 Service Road East Lansing, MI 48824 USA Tel: (517) 353-8122 Fax: (517) 432-3713 Acknowledgements: This work was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc., New York City, NY (to AGL). Copyright: Copyright 2017 Elsevier B.V., All rights reserved.",

year = "1999",

doi = "10.1076/noph.22.1.37.3741",

language = "English (US)",

volume = "22",

pages = "37--46",

journal = "Neuro-Ophthalmology",

issn = "0165-8107",

publisher = "Taylor and Francis Ltd.",

number = "1",

}

TY - JOUR

T1 - Cabergoline in prolactinomas

AU - Fierz, Anna B.

AU - Kaufman, David I.

AU - Lee, Andrew G.

AU - Eggenberger, Eric R.

AU - Friend, Keith E.

N1 - Funding Information: Dr. D.I. Kaufman Professor and Director Center for Clinical Neurosciences and Ophthalmology A-217 Clinical Center 138 Service Road East Lansing, MI 48824 USA Tel: (517) 353-8122 Fax: (517) 432-3713 Acknowledgements: This work was supported in part by an unrestricted grant from Research to Prevent Blindness, Inc., New York City, NY (to AGL). Copyright: Copyright 2017 Elsevier B.V., All rights reserved.

PY - 1999

Y1 - 1999

N2 - Cabergoline is a potent, D2-selective new dopamine agonist with a half- life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.

AB - Cabergoline is a potent, D2-selective new dopamine agonist with a half- life of 65 hours. We report two cases and review the literature on cabergoline in prolactinomas. Cabergoline appears to be more effective and better tolerated than bromocriptine, compliance may be improved, and costs are comparable. In cases of bromocriptine failure, unusually high starting doses of cabergoline may be necessary. Cabergoline may eventually replace bromocriptine as the drug of choice in prolactinomas.

KW - Bromocriptine resistance

KW - Cabergoline

KW - Metastatic prolactinomas

KW - Prolactinomas

UR - http://www.scopus.com/inward/record.url?scp=0032760064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032760064&partnerID=8YFLogxK

U2 - 10.1076/noph.22.1.37.3741

DO - 10.1076/noph.22.1.37.3741

M3 - Article

AN - SCOPUS:0032760064

SN - 0165-8107

VL - 22

SP - 37

EP - 46

JO - Neuro-Ophthalmology

JF - Neuro-Ophthalmology

IS - 1

ER -

Cabergoline in prolactinomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this